RBC's Bri­an Abra­hams holds a mock ad­comm on Bio­gen's iffy ad­u­canum­ab da­ta — and most of these ex­perts don't see a path to an ap­proval

As cat­a­lysts go, few loom larg­er than the ad­u­canum­ab ad­comm slat­ed for Nov. 6.

With its big fran­chise un­der as­sault, Bio­gen is bet­ting the ranch that its mixed late-stage Alzheimer’s da­ta can squeak past the ex­perts and reg­u­la­tors and get on­to the mar­ket. And the top­ic — af­ter a decade of Alzheimer’s R&D dis­as­ters in what still rep­re­sents the El Do­ra­do of drug mar­kets — re­mains in the cen­ter ring of dis­cus­sions around late-stage pipeline prospects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.